Contrast Media Market

Contrast Media Market Overview

The global contrast media market, valued at USD 6.38 billion in 2024, is expected to grow to USD 6.83 billion in 2025 and USD 11.88 billion by 2035, representing a CAGR of 5.7% during the forecast period.

To learn more about this report, request a free sample copy

Contrast media is a contrast agent that is used to enhance diagnostic value particularly in imaging-based examination. These contrast media modify the magnetic properties of the water molecules within organ, creating a contrast for better images of the organs and blood vessels. The ability to provide well contrasting images from image examinations such as computer tomography (CT), ultrasound, X-ray and magnetic resonance imaging (MRI) has made these materials an important part of imaging diagnostics.

It is important to highlight here that contrast media such as iodinates and gadolinium-based contrast media has been widely adopted for radiology practices specifically image examination. These materials are relatively safe and offer accurate diagnostic images, which make them an invaluable media for diagnostics. According to the recent report of Centers for Disease Control and Prevention, over 944,800 Americans die due to heart stroke annually and around 90% (approximately USD 4.5 trillion) of nations healthcare expenditure is dedicated to people with mental and chronic health conditions. With the growing incidence of chronic conditions, there is surge in the demand for advanced imaging materials and technologies that aid in diagnosis accurately. Furthermore, with the rising adoption of teleradiology services and digital diagnostics solutions, contrast media / agents are gaining momentum.

Considering the ongoing demand, several industrial players are taking strategic initiatives followed by latest product launch, collaborations and partnerships to strengthen product portfolio. For instance, in November 2024, Bayer announced 510(k) clearance from the USA for MEDRAD® Centargo CT injection system (a multi-patient contrast injector). This contrast injection system features piston-based technology to deliver contrast media and saline simultaneously, offering flexibility in imaging process specifically for contrast enhanced mammography (breast imaging).

In addition to the FDA approval, several industrial players are aiming to enhance their production facilities to meet the growing demand for contrast media. For instance, in November 2024, Bracco announced that the company invested more than 80 million euros to build Hexagon (a new multi-functional facility) next to its historical 1996 plant. This new multi-functional building when fully operated will triple the production and supply of contrast agents for ultrasound based on microbubbles for real time diagnosis. Considering the ongoing initiatives, we believe that the contrast media market will remain progressive and investible for a long period of time.

Contrast Media Market Segmentation Overview

The market report provides in-depth information on the key players of the industry who are presently active across different segments as discussed in the table below.

Contrast Media Market: Report Attributes / Market Segmentation

Key Report Attributes	Details
Historical Trend	Since 2019
Forecast Period	Till 2035
Current Market Size	USD 6.83 Billion
Market Size 2035	USD 11.88 Billion
CAGR (Till 2035)	~5.7%
Type of Imaging Modality	Ultrasound Magnetic Resonance Imaging X-Ray / Computed Tomography
Type of Contrast Media	Iodinated Contrast Media Gadolinium-Based Contrast Media Microbubble Media Barium-Based Media
Type of Contrast Media Form	Tablet Liquid Powder Paste
By Route of Administration	Intravenous Oral Route Rectal Route
By Therapeutic Area	Cardiovascular Disorders Neurological Disorders Gastrointestinal Disorders Cancer Nephrological Disorders Musculoskeletal Disorders Other Disease Indications
Type of Application	Radiology Interventional Radiology Interventional Cardiology
Type of End User	Hospitals Diagnostic Imaging Centers Other End Users
Key Geographical Region	North America (US, Canada and Mexico) Europe (Germany, France, Italy, Spain, UK and Rest of Europe) Asia-Pacific (China, India, Japan and Rest of the Asia-Pacific) Midde East and North Africa (Egypt, Saudi Arabia and UAE) Latin America (Argentina and Brazil)
Key Companies Profiled	Bayer Bracco GE HealthCare Guerbet iMAX Diagnostic Imaging J.B. Chemicals & Pharmaceuticals Jodas Expoim Lantheus Holdings Livealth Biopharma nanoPET Pharma Senochemia Spago Nanomedical TAEJOON Pharmaceutical Trivitron Healthcare Unijules Life Sciences (A full list of key companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

One of the key objectives of the contrast media market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

Additionally, the market report features the likely distribution of the current and forecasted opportunity within the market distributed across various segments such as type of imaging modality (ultrasound, magnetic resonance imaging and X-ray / computed tomography), type of contrast media (iodinated contrast media, gadolinium-based contrast media, microbubble media and barium-based media) type of contrast media form (tablet, liquid, powder and paste), type of route of administration (intravenous, oral route and rectal route), therapeutic area (cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders and other indications), type of application (radiology, interventional radiology and interventional cardiology), end user (hospitals, diagnostic imaging centers and other end users), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), and leading players.

To account for the uncertainties associated with the development of advanced contrast media solutions and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Contrast Media Market Share Insights

Market Share by Type of Imaging Modality

Based on the type of imaging modality, the global contrast media market is segmented into ultrasound, magnetic resonance imaging and X-ray / computed tomography. According to our projection, currently X-ray / computed tomography accounts for the highest share (nearly 60%) of the market. This can be attributed the fact that contrast media is widely used to create high-resolution 3D images of internal body structures. Further, organs like stomach and colon are unable to block X-rays, therefore contrast medium such as barium-based / iodinated contrast agent is used along with X-ray / computed tomography to highlight the specific organs of the body.

However, it is important to highlight here that the ultrasound segment is expected to register a higher CAGR during the forecast period. This is primarily due to the increasing usage of contrast media to visualize microcirculation in tissues. Furthermore, when contrast media is combined with imaging modalities such as microbubbles help to enhance echogenicity of the blood which further enhance imaging of large vessels and cardiac cavities.

Market Share by Type of Contrast Media

This segment highlights the distribution of global contrast media market size across different types of contrast media, such as iodinated contrast media, gadolinium-based contrast media, microbubble media and barium-based media. According to our market study, presently iodinated contrast media holds the highest share (nearly 55%) of the market. This can be attributed to the high penetration and contrasting ability of iodinated contrast media with computed tomography and X-ray. Additionally, iodinated contrast media is widely adopted for the accurate visualization of internal organs and Gastrointestinal tract and arteries & veins.

However, in the long run, it is estimated that microbubble contrast media segment will register a higher CAGR during the forecast period. These microbubble based contrast media offer brighter appearance of internal structure by reflecting ultrasound waves. Microbubble contrast media increase echogenicity of the blood and use for imaging of the heart. This contrast media is often applicable for patients with allergic conditions which might rise its demand in the future.

Market Share by Type of Contrast Media Form

The global market is distributed across different types of contrast media forms such as tablet, liquid, powder and paste. Among these, liquid form accounts for the highest contrast media market share (nearly 70%), driven by the ease of administration and fast dissolving capabilities. Moreover, it can be administered through multiple routes such as oral route, intravascular route and rectal route. In addition, liquid forms offer high contrasting images and clear visualization of organs during X-ray / computed tomography which further helps in accurate diagnosis. Driven by the significances, this segment will continue to gain momentum and is likely to grow at a higher CAGR during the forecast period.

Market Share by Route of Administration

On the basis of route of administration, the global contrast media market is distributed across intravenous, oral route and rectal route. According to our projection, intravenous route holds the highest share (nearly 50%) of the market. This can be attributed to the fact that intravenous route is highly suitable to deliver iodinated contrast media and other contrast media for evaluating diseases. Moreover, intravenous route offers several advantages such as rapid dissolving which makes it ideal for CT scanning of pelvis, chest and lower extremities. In addition, intravenous route is widely used for selective imaging of organs or cerebral angiography. Driven by widespread usage, this segment will continue to grow at a substantial CAGR during the forecast period.

Market Share by Therapeutic Area

Based on the therapeutic area, the global market is segmented into cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders and other disease indications. According to our projection, currently neurological disorders account for the highest contrast media market share (nearly 30%). This is primarily due to widespread adoption of contrast media for diagnosing neurodegenerative diseases, brain tumors and stroke. Contrast media offer high contrasting images which makes it valuable for evaluating brain structure and pathology. Owing to its high contrasting abilities, contrast media is widely used for neurological imaging, thereby contributing to the higher share.

However, in the long run, we believe that cardiovascular disorder segment is estimated to grow at a higher CAGR during the forecast period. This can be attributed to the growing incidence of cardiovascular disorders across the globe which necessitated the demand for advanced imaging solutions for accurate diagnosis.

Market Share by Type of Application

On the basis of application, the global contrast media market is segmented into radiology, interventional radiology, interventional cardiology. According to our projection, interventional radiology accounts for the highest share of the market. This can be attributed to the growing usage of radiology examination for early detection of a wide range of diseases such as cardiovascular disorders and neurological disorders. In addition, interventional radiology is also widely supported by healthcare practitioners for disease diagnosis. However, it is worth mentioning here that interventional cardiology segment is anticipated to witness a higher CAGR during the forecast period owing to the growing usage of contrast media agents with CT scan and X-rays for enhanced visualization of arteries and veins.

Market Share by End User

The global contrast media market size is further categorized based on the end user into hospitals, diagnostic imaging centers and other end users. According to our projection, currently hospitals account for the largest share (nearly 60%) of the market. This can be attributed to the hospitals have large pool of patients and with rising burden of diseases, clinicians are adopting advanced automated radiological technologies and solutions for accurate diagnosis. However, in the long run, it is expected that diagnostic imaging centers segment is likely to grow at a higher CAGR during the forecast period. This is likely to be the result of growing preferences for comprehensive diagnostic services and demand for outpatient diagnostics facilities for quick diagnosis and better treatment.

Market Share by Geographical Region

Based on the geographical region, the global contrast media market is distributed across key geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our projection, currently North America accounts for the highest share (35%) of the market. This can be attributed to the presence of advanced healthcare infrastructure and rising adoption of digital technologies for disease diagnosis and treatment planning. Additionally, the presence of well-established players like Bayer, Pfizer and GE Healthcare who are continually increasing their research on advanced contrast media solutions for high contrast images is contributing to the highest growth rate of the market.

However, in Asia-Pacific, the market for contrast media is anticipated to grow at a higher CAGR during the forecast period. This is likely to be the result of growing demand for advanced diagnostics procedures for accurate treatment planning. Furthermore, the rising prevalence of chronic diseases in Asian countries has necessitated the demand for advanced contrast media for diagnostic imaging.

Contrast Media Market Dynamic Insights

The “Contrast Media Market: Industry Trends and Global Forecasts, till 2035” market research report features an extensive study of the focus on competitive landscape of strategic initiatives, emerging mega trends, big pharma initiatives, company profiles and key drivers and restraints. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the contrast media industry. Key takeaways of the market report are briefly discussed below.

Contrast Media Market Competitive Landscape

Currently, the global market landscape is highly competitive witnessing the presence of several small, mid-sized and large companies. These market players are focusing on the development of advanced contrast media with higher efficacy and media delivering technologies. In order to leverage the competitive edge, several industrial players are focusing on strategic partnerships, collaborations and partnerships to enhance product portfolio. For instance, in April 2024, Bayer and Hologic entered into a collaboration for delivering coordinated solutions for contrast-enhanced mammography. Overall, the market seems highly consolidated with the presence of well-established and new entrants.

Market Drivers: High Demand for Advanced Contrasting Agents, Rising Prevalence of Chronic Diseases and Imaging Technology Innovations

The market for contrast media is primarily driven by the growing incidence of chronic diseases and rising demand for advanced contrasting agents for accurate diagnostics. Furthermore, the increasing requirement for innovative imaging technologies for detailed imaging has further underscored the demand for novel contrast agents. In addition, the increasing expenditure on cutting-edge diagnosing technologies that allow more detailed examination of diseases has further encouraged the adoption of contrast media, which is anticipated to be a key growth factor for the market.

Market Challenges: High Cost and Side Effects Associated with Contrast Media

Despite the growing demand, there are some challenges that may impede contrast media market growth during the projected period. Some of the notable challenges are high cost of contrast media and side effects associated with these agents. Although contrast media / contras agents are safe to use or diagnostics procedures, these materials pose a risk of side effects and allergic reactions. These side effects or allergic reactions may be moderate to severe, however, severe allergic reactions are still rare.

Market Trends: Optimal Contrast Media Delivery Technology, Photon Counting CT and Artificial Intelligence

Considering the side effects of contrast media, industrial players are focusing on optimal contrast media delivery technologies that aid in delivering appropriate dosage of these agents. Furthermore, several market players are focusing on introducing technologies such as smart injection systems, Photon-counting CT and AI applications that lower the iodine dose without altering the accuracy rate of diagnosis. Additionally, researchers are emphasizing on the development of innovative contrast medias for diagnosis of specific diseases and tissues, which is anticipated to offer enormous opportunities to industrial players for taking strategic initiatives.

Contrast Media Market Size Analysis

Currently, the global contrast media market is estimated to be valued at USD 6.83 billion and is poised to reach USD 11.88 billion by 2035. Driven by the increasing demand for advanced contrast agents that can combine with X-ray, CT scanners and MRI to improve diagnosing images, the market for contrast media is expected to grow at a CAGR of 5.7% during the forecast period. It is important to highlight here that several industrial players are aiming to enhance the product portfolio of contrast media technologies. For instance, in October 2024, GE HealthCare announced Phase I clinical trial positive results for a manganese-based MRI contrast agent for improved diagnosis.

Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics business segment, said, “These are encouraging Phase I results for this manganese-based contrast agent and we look forward to completing the next steps in the clinical development process. This is part of our pipeline of products aiming to improve patient outcomes across care pathways.”

Owing to the growing clinical trials and rising adoption of contrast media, we believe that contrast media market is expected to remain competitive during the projected period.

Leading Companies in Contrast Media Market

Examples of key players engaged in the contrast media industry (which have also been captured in this report) include Bayer, Bracco, GE HealthCare, Guerbet, iMAX Diagnostic Imaging, J.B. Chemicals & Pharmaceuticals, Jodas Expoim, Lantheus Holdings, Livealth Biopharma, nanoPET Pharma, Senochemia, Spago Nanomedical, TAEJOON Pharmaceutical, Trivitron Healthcare and Unijules Life Sciences. This market report includes an easily searchable excel database of all the companies focusing on advanced contrast media.

Contrast Media Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, Contrast Media Market, 2019-2025 (Historical Trends), and Future Forecast till 2035 (Forecasted Estimates).
• An outline of the systematic research methodology adopted to conduct the study on the contrast media, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure the accuracy and reliability of our findings.
• An overview of economic factors that impact the overall market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view of the current state of the contrast media market and its evolution in the mid-and long-term.
• A detailed assessment of the market landscape of companies developing contrast media is based on several relevant parameters, including years of experience, company size, headquarters location, and ownership structure.
• Elaborated profiles of prominent players engaged in offering contrast media products, featuring information on their year of establishment, location of headquarters, company size, company mission, company footprint, management team, contact details, financial information, operating business segments, contrast media product portfolio, recent developments, and an informed future outlook.
• A discussion on affiliated trends, key drivers, and challenges under a SWOT framework, which is likely to impact the industry's evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall contrast media industry.
• A market impact analysis features a discussion on the factors that can impact the growth of contrast media market.
• A detailed estimate of the current market size and the future growth potential of the market for contrast media over the next decade. Based on multiple parameters, we have provided an informed estimate of the market's evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunities within the contrast media industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future contrast media market across various types of imaging modality, including ultrasound, magnetic resonance imaging and x-ray / computed tomography.
• Detailed projections of the current and future contrast media industry across different types of contrast media, including iodinated contrast media, gadolinium-based contrast media, microbubble media and barium-based media.
• Detailed projections of the current and future market for contrast media across various types of contrast media form, including tablet, liquid, powder and paste.
• Detailed projections of the current and future contrast media market across different types of route of administration, including intravenous, oral route and rectal route.
• Detailed projections of the current and future market for contrast media across different therapeutic areas, including cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders and other disease indications.
• Detailed projections of the current and future contrast media market across different types of end user, including hospitals, diagnostic imaging centers and other end users.
• Detailed projections of the current and future market for contrast media across various key geographical regions, such as North America (US, Canada and Mexico), Europe (France, Germany, Italy, Spain, UK and Rest of the Europe), Asia-Pacific (China, India, Japan, and Rest of the Asia-Pacific), Middle East and North Africa (Egypt, Saudi Arabia and UAE), and Latin America (Argentina and Brazil).

Recent Developments in Contrast Media Market

Several recent developments have taken place in the field of contrast media. We have outlined some of these recent initiatives below.

• In December 2024, Voyageur Pharmaceuticals announced that the company has signed a letter of intent with a major multinational pharmaceutical company to increase its production of contrast media products.
• In October 2024, Guerbet (specialized in contrast media and solutions) announced that Gadopiclenol (ELucirem®) has been awarded with the JFR*2024 Innovation Award. This advanced contrast agent offers high stability, relaxivity and high contrasting images.
• In May 2024, Ascelia Pharma announced that its Orviglance successfully completed the endpoint goal of pivotal Phase III study. The candidate demonstrated improved visualization of focal liver lesions with Orviglance (CMRI).